circadian rhythm is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
=== Sentencing and imprisonment === On August 16, 2010, Judge Keenan sentenced Banki to 30 months in prison. Shortly after being sentenced Banki filed for appeal. The Iranian American Bar Association along with 10 other advocacy and civil rights groups filed a separate amicus brief with the United States Court of Appeals for the Second Circuit. The brief argued that U.S.-Iran sanctions "are not aimed at the Iranian people, and therefore they contain exemptions permitting certain humanitarian transactions and family remittances." For about 11 months (from January 7, 2010, through December 1, 2010) Banki was held in high and maximum security detention centers in Manhattan and Brooklyn (MCC and MDC) with BOP# 63037-054. For the month of December in 2010, Banki was transferred to the Taft Correctional Institute's deportation prison outside of Bakersfield in California. In January 2011, Banki was transferred to the lower security Taft prison where he remained pending the appellate decision. Upon release Banki had served 665 days, nearly 22 months in prison.
DMT binds non-selectively with affinities below 0.6 μmol/L to the following serotonin receptors: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, and 5-HT7. An agonist action has been determined at 5-HT1A, 5-HT2A and 5-HT2C. Its efficacies at other serotonin receptors remain to be determined. Of special interest will be the determination of its efficacy at human 5-HT2B receptor as two in vitro assays evidenced DMT's high affinity for this receptor: 0.108 μmol/L and 0.184 μmol/L. This may be of importance because chronic or frequent uses of serotonergic drugs showing preferential high affinity and clear agonism at 5-HT2B receptor have been causally linked to valvular heart disease. It has also been shown to possess affinity for the dopamine D1, α1-adrenergic, α2-adrenergic, imidazoline-1, and σ1 receptors. Converging lines of evidence established activation of the σ1 receptor at concentrations of 50–100 μmol/L. Its efficacies at the other receptor binding sites are unclear. It has also been shown in vitro to be a substrate for the cell-surface serotonin transporter (SERT) expressed in human platelets, and the rat vesicular monoamine transporter 2 (VMAT2), which was transiently expressed in fall armyworm Sf9 cells. DMT inhibited SERT-mediated serotonin uptake into platelets at an average concentration of 4.00 ± 0.70 μmol/L and VMAT2-mediated serotonin uptake at an average concentration of 93 ± 6.8 μmol/L.
Originally a Russian production, all in Russian with subtitles, produced by Maciej Drygas 15 October High Anxiety, about lifts and the required extensive technology of tall office buildings; Canary Wharf Tower (One Canada Square) had 50 floors with 36 lifts, which could travel up to 13.5 mph; Jim Fortune of Lerch Bates; novelist Philip Kerr; Otis Elevators alarm response centre of Farmington, Connecticut, which dealt with trapped passengers - it took about 20 minutes to rescue people; the Otis Test Tower, at Bristol in Connecticut, which had 29 floors and 11 lifts; architect Ken Yeang of Malaysia, known for his tall buildings; Gary Faltin of Otis; in the distant past, due to ropes, only goods were carried by lifts; in 1853 Elisha Otis invented a safety system for lifts, via a governor cable; only once have steel lift cables snapped, on 28 July 1945, in the 1945 Empire State Building B-25 crash after being lost in fog, severing the lift governor cable; if the cable snapped, due to the lift being balanced only after about nine people were in a lift, the lift would go upwards; on 12 August 1995, in the Empire State Building, a lift did go upwards, to be trapped at the 80th floor; the Woolworth Building, with 57 floors and 26 lifts, which could travel up to 10 mph - it was the world's tallest building from 1911 to 1930; engineer William Sheeran of Otis; medical doctor Rollin Stott, of the Linear Motion Laboratory of the Defence Research Agency (DERA) Centre for Human Sciences in north-east Hampshire; the feelings in the stomach, often sensed in a lift, comes from a pulse of adrenaline; Convent of Sacred Heart, with six floors; Nicole Fenchel was phobic of lifts; Doreen Powell of White Plains Hospital; the express lift, for the observation platform, in Tower 2 of the former World Trade Center had a journey time of 58 seconds; the former WTC had the world's second and third tallest office buildings; Tower 1 had 110 floors, being 417 metres high, with 96 lifts that could travel up to 15 mph; 70,000 people worked in the former WTC; people should not have to wait for a lift for no more than 30 seconds; Roger Howkins of Arup in London; 200 Vesey Street, known as Three World Financial Center, with 51 floors and 39 lifts, that could travel up to 14 mph; the former WTC was the first building to introduce the sky lobby design, with interspersed lifts; Robert DiChiara, assistant director of the former WTC; engineer Bruce Powell of Otis; Argentine architect, César Pelli, who designed One Canada Square of Canary Wharf; control systems of lifts anticipated demand; but there was a dark and menacing side to travel by lifts - Detectives Kevin Dineen and Lisa McClean of the NYPD Elevator Squad, at Carver Houses in the East Village, Manhattan, and how criminals could isolate victims; local youths and children would travel on top of the elevators for momentary thrills; the New York Marriott Marquis hotel, with 49 floors and 12 elevators, which could travel up to 15 mph; the Petronas Towers in Malaysia, with 88 floors, and 76 lifts, that could travel up to 16 mph, to be completed by 1997; lift ropes could go up to 600 metres, at the extreme most; new lifts would be powered by tubular linear motors or AC induction motors; 600 lifts with these new motors were operating in Japan; Yebisu Garden Place in Ebisu, Shibuya in Tokyo, where linear motors powered the lift counterweight; the Nishi-Shinjuku district in Shinjuku, Tokyo; many tall buildings were being built in Japan; Riverside Sumida Center, of Tokyo, built in 1994; the Yokohama Landmark Tower, with 70 floors, in Japan, built in 1993; Mitsubishi Electric had the world's fastest lifts, up to 28 mph; Junichi Sato of Mitsubishi, who said that he thought that Japanese people valued well-made products, and only trusted manufacturers too, whereas he thought that Americans and Europeans merely wanted functional products, whether good or not; the proposed enormous 800 metre Millennium Tower (Tokyo) for Tokyo Bay, with 150 floors, which was never built, but the Gherkin (30 St Mary Axe) was built instead; architect Andrew Miller of Foster Asia; there were twenty buildings over 60 floors being built; the Chinese economy was growing by 15% per year, and was Mitsubishi's biggest customer; the Century Tower (Tokyo), built in 1991, with 21 floors, with 14 lifts, that could travel up to 11 mph; lift technology had allowed Western business to prosper, but now it was superfluous for Western business. Narrated by Paul McGann, produced by Elizabeth Allen, directed by Gary Johnstone, made by Diverse Productions 22 October DNA in the Dock, an Equinox Special that was an update on the Incredible Evidence episode on 28 December 1994; The murder of 15-year-old Claire Hood, last seen on 19 January 1995, where 2,100 men had their DNA tested; her body was found in Cath Cobb Woods the next day; Sir Alec Jeffreys claimed that he could tell anyone apart; Timothy Wilson Spencer was the first person to be executed, with DNA evidence, on 27 April 1994, having committed murder in 1988; DCI Stuart Lewis, who worked on the Claire Hood investigation, who believed that her killer lived nearby - her killer lived 100 yards away; the United Kingdom National DNA Database began earlier in 1995, and in six months, 60,000 DNA specimens were recorded, and the database was intended to have 5 million specimens; an investigation of Orchid Cellmark, part of ICI, found that errors in correlation of specimens were made; California police gave test specimens to Cellmark, and errors were found, which Cellmark attributed to cross-contamination; Donald Findlay and a Scottish rape investigation in Largs, North Ayrshire, in 1987; former policeman Brian Kelly, and his wrongful conviction, for six years, serving four of them, for rape on 30 November 1989, through DNA evidence alone - DNA testing would later change in 1990, where crime scene DNA specimens were kept apart; Kary Mullis, who invented the PCR test in 1983, receiving the 1993 Nobel Prize in Chemistry, and knew about errors in DNA genetic testing; David Werrett of the Forensic Science Service, who set up the UK national DNA database in Birmingham, which deployed the PCR method - the more reliable Second Generation Multiplex Plus would be later introduced in 1999; Don Dovaston, later the deputy chief of Derbyshire Constabulary, which was the first police force to identify suspects through the UK DNA database; the Metropolitan Police had its own DNA database; Larry Mueller, population geneticist at the UCI School of Biological Sciences. Produced by David Poyser, directed by Hilary Lawson, made by TVF 5 November Kaboom!, the explosives engineer Sidney Alford; Controlled Demolition, Inc., founded by Jack Loizeaux; Rev Ron Lancaster, originally from Huddersfield, who founded Kimbolton Fireworks in 1964, when a chemistry teacher at Kimbolton School; in 1847 Ascanio Sobrero of Italy discovered nitroglycerin - nitroglycerin is the main component of dynamite; a detonation occurs at supersonic speed; Semtex was developed in Czechoslovakia in the 1960s; Ballistite, made from nitroglycerin and discovered in 1887, is the propellant for guns. Joint-production with NOVA and WGBH. Shown on Nova on 14 January 1997 12 November Avalanche, avalanches kill around two hundred people a year, with 120 of those in the Alps; Swiss physicist Othmar Buser of the Swiss Federal Institute for Forest, Snow and Landscape Research (WSL), who developed a database of avalanches; Bruce Tremper; Doug Fesler; powder snow avalanches can reach 150 mph; Laurent Buisson. Narrated by Heather Couper, made by Pioneer Productions with Discovery Networks 19 November God only Knows, about how some physicists see theology being explained through physics, such as Frank J. Tipler of Tulane University and his book The Physics of Immortality; George Johnson (writer) and book titles; Lewis Wolpert and how there was no evidence for God in the external world; David Finley of the National Radio Astronomy Observatory; religious writer Karen Armstrong, author of A History of God; Brazilian physicist Marcelo Gleiser; physicist Leon M. Lederman; Russell Stannard and physics before the big bang; the KTeV experiment at Fermilab, which looked at kaons, and Vivian O'Dell; Rev John Polkinghorne, former professor of Mathematical Physics at the University of Cambridge. Narrated by Bill Paterson, produced by Nicolas Kent, directed by Peter Webber 26 November Gloria's Toxic Death, about the death of Gloria Ramirez in California on 19 February 1994; a nurse, who took a blood sample from her, passed out from inhaling an unknown vapour coming from the blood sample; few episodes of Doctor Who had such a bizarre and unbelievable storyline; blood tests from the nurses revealed a lowering of the enzyme cholinesterase, which in other cases is linked to organophosphate poisoning; the Lawrence Livermore National Laboratory proposed a connection to dimethyl sulfoxide (DMSO) that had combined with oxygen given in the hospital to make dimethyl sulfate; the conditions of the hospital were repeated in a test, and the results underwent gas chromatography–mass spectrometry by Yolanda de Miguel at Department of Chemistry, Imperial College London. Narrated by Neil Pearson, directed by Tim Shawcross, produced by Geoff Deehan, made by Union Pictures with Discovery Communications 3 December On Jupiter, about the large gravitational effect that Jupiter has on the solar system; if the mass of Jupiter was thirty times bigger, the heat in its centre could sustain nuclear reactions, and it could become a star, maybe a brown dwarf; Gene Shoemaker of the Lowell Observatory and Palomar Observatory; Galileo Galilei discovered Jupiter's moons, Io, Europa, Ganymede (the largest moon in the solar system), and Callisto, on 7 January 1610; Heidi Hammel of MIT; Galileo (spacecraft), built at JPL and Ames in the 1980s, being planned to have launched in 1982, arrived at Jupiter on 7 December 1995; Torrence Johnson of JPL; Jim Scotti of the Spacewatch project at Kitt Peak National Observatory; Brian G. Marsden of the Central Bureau for Astronomical Telegrams; Vicki Meadows of the Anglo-Australian Telescope; Imke de Pater of the W. M. Keck Observatory on Mauna Kea; David Morrison (astrophysicist) of NASA Ames. Narrated by John Hurt, directed by Richard Smith, made by Pioneer Productions and the Discovery Channel 10 December Designing Dream Machines, about product innovation and product design of food processors and a reinvented motorbike by the Seymour-Powell design agency and its designer Nick Talbot, with the management team of Tefal UK and its managing director and a design by 43-year-old Dick Powell, and a possible new design of the ubiquitous 125CC BSA Bantam motorbike for MZ Motorrad- und Zweiradwerk of Germany by 42-year-old Richard Seymour; the 59 Club; Leigh Martin of the defunct Comet (closed in December 2012). Narrated by Marilyn Milgrom, directed by Richard Burke, produced by Richard Reisz. TV6 went on to make the six-part series Better by Design 17 December It Runs on Water, about the field commonly known as fringe science, where physicist Frank Close was sceptical if not broadly dismissive, stating that 300 years of science could not be overruled, but a professor of Aeronautics Paul Csysz of Saint Louis University mentioned that he thought some people in science were often unquestioning of their lifelong-held beliefs, and nervous of anyone trying to do so; an invention in Moscow was looked at by American physicist Harold E. Puthoff; Stanley Meyer's water fuel cell; NASA's propulsion research at Lewis Research Center in Cleveland, Ohio; it ends with Sir Arthur C. Clarke and Requiem (Mozart). Directed by Lawrence Simanowitz, produced and narrated by William Woollard, made by InCA Productions with Discovery Communications 20 December Do Vampire Bats have Friends?, an Equinox Special about whether animals have consciousness; zoologist Prof John Krebs, Baron Krebs, and whether animals had human-like sentience; biologist Gerald Wilkinson of the University of Maryland, and research, over five years, into relationships of vampire bats with other types of animals, and found food sharing between hungry vampire bats; zoologist Miriam Rothschild; psychologist Cecilia Heyes of UCL and self-perception of chimpanzees; zoologist Bernd Heinrich of the University of Vermont, and puzzle-solving of raven birds; zoologist Benjamin Beck of The National Zoo, and the apparent deployment of tools by animals; Ian Farquhar, and foxhunting, and whether foxes realise their predicament, and the Duke of Beaufort's Hunt in Gloucestershire; biologist Sir Patrick Bateson of the University of Cambridge, sensation of pain in animals, and the Animals (Scientific Procedures) Act 1986, which defined protected animals, that did not cover the octopus, but due to research by the Universities Federation for Animal Welfare (UFAW); Prof Peter Boyle and Martin Wells, and a 1993 amendment added the octopus; Prof Daniel Dennett of Tufts University, and how snakes think; psychologist Irene Pepper berg, of the University of Arizona, and an African Grey parrot called Alex, who has been talking for 18 years; the horse Clever Hans; Robert Seyfarth (scientist) and Dorothy Cheney (scientist), and their work on baboon warning calls and grunts, in Kenya. Narrated by Andrew Sachs, directed by Christopher Sykes, made by Christopher Sykes Productions
Proline (symbol Pro or P) is an organic acid classed as a proteinogenic amino acid (used in the biosynthesis of proteins), although it does not contain the amino group -NH2 but is rather a secondary amine. The secondary amine nitrogen is in the protonated form (NH2+) under biological conditions, while the carboxyl group is in the deprotonated −COO− form. The "side chain" from the α carbon connects to the nitrogen forming a pyrrolidine loop, classifying it as a aliphatic amino acid. It is non-essential in humans, meaning the body can synthesize it from the non-essential amino acid L-glutamate. It is encoded by all the codons starting with CC (CCU, CCC, CCA, and CCG). Proline is the only proteinogenic amino acid which is a secondary amine, as the nitrogen atom is attached both to the α-carbon and to a chain of three carbons that together form a five-membered ring.
Vitamin C was discovered in 1912, isolated in 1928 and synthesized in 1933, making it the first vitamin to be synthesized. Shortly thereafter Tadeus Reichstein succeeded in synthesizing the vitamin in bulk by what is now called the Reichstein process. This made possible the inexpensive mass-production of vitamin C. In 1934, Hoffmann–La Roche bought the Reichstein process patent, trademarked synthetic vitamin C under the brand name Redoxon, and began to market it as a dietary supplement. In 1907, a laboratory animal model which would help to identify the antiscorbutic factor was serendipitously discovered by the Norwegian physicians Axel Holst and Theodor Frølich, who when studying shipboard beriberi, fed guinea pigs their test diet of grains and flour and were surprised when scurvy resulted instead of beriberi. Unknown at that time, this species did not make its own vitamin C (being a caviomorph), whereas mice and rats do. In 1912, the Polish biochemist Casimir Funk developed the concept of vitamins. One of these was thought to be the anti-scorbutic factor. In 1928, this was referred to as "water-soluble C", although its chemical structure had not been determined.
Sources: en.wikipedia.org
In case of above-normal intraocular pressure, the mechanism of open-angle glaucoma is believed to be the impeded exit of aqueous humor through the trabecular meshwork, while in closed-angle glaucoma, the iris blocks the trabecular meshwork. Diagnosis is achieved by performing an eye examination. Often, the optic nerve shows an abnormal amount of cupping.
NL is diagnosed by a skin biopsy, demonstrating superficial and deep perivascular and interstitial mixed inflammatory cell infiltrate (including lymphocytes, plasma cells, mononucleated and multinucleated histocytes, and eosinophils) in the dermis and subcutis, as well as necrotising vasculitis with adjacent necrobiosis and necrosis of adnexal structures. Areas of necrobiosis are often more extensive and less well defined than in granuloma annulare. The presence of lipid in necrobiotic areas may be demonstrated by Sudan stains. Cholesterol clefts, fibrin, and mucin may also be present in areas of necrobiosis. Depending on the severity of the necrobiosis, certain cell types may be more predominant. When a lesion is in its early stages, neutrophils may be present, whereas in later stages of development, lymphocytes and histiocytes may be predominant.
=== Contributions to mechanical properties of biomaterials === Natural materials show a combination of normally contradicting mechanical properties (softness and toughness), due to their hierarchical structures of fibrils across multiple length scales. These fibrils are often oriented in a single direction, leading to anisotropic mechanical response in the resulting biocomposite material. This is a prime advantage as most of these materials withstand stresses in a single direction, and so a higher yield and fracture stress in the direction of the applied stress ensures the material structural integrity. Macro, micro, and nano fibrils enable the material to resist fracture through a series of fracture resistance mechanisms:
Bone is metabolically active tissue composed of several types of cells. These cells include osteoblasts, which are involved in the creation and mineralization of bone tissue, osteocytes, and osteoclasts, which are involved in the reabsorption of bone tissue. Osteoblasts and osteocytes are derived from osteoprogenitor cells, but osteoclasts are derived from the same cells that differentiate to form macrophages and monocytes. Within the marrow of the bone there are also hematopoietic stem cells. These cells give rise to other cells, including white blood cells, red blood cells, and platelets.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.